Glutathione: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. Glutathione is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

• Oral dose–response in rats: Single oral doses at 0.4, 1, and 4 mmol/kg GSH (≈123, 307, and 1,229 mg/kg) showed dose‑dependent increases in tissue GSH (notably jejunum, lung, heart, liver, brain), peaking around 90 min. In BSO‑depleted animals, oral GSH partially restored tissue GSH; responses were saturable at higher doses, suggesting transport and enzymatic constraints. Co‑administration with γ‑glutamyltranspeptidase inhibitor (AT125) modulated organ responses, supporting distinct uptake mechanisms.

• Intraperitoneal dosing in rats (toxin models): Experimental IP GSH at 500 mg/kg was used to mitigate cisplatin nephrotoxicity (nephroprotection reported; study details required for precise effect sizes). In another cisplatin neurotoxicity model with repeated 2 mg/kg/week cisplatin, GSH administered shortly before chemotherapy reduced neurotoxicity; protection appeared timing‑dependent. These IP and pre‑treatment paradigms indicate high‑dose GSH has protective effects against platinum toxicity, though quantitative dose–response within GSH arms was not delineated in the excerpts (details summarized in the table).

• Oral nanoformulations: In rats, niosomal (nano) GSH at about 100 mg/kg orally improved hepatoprotection versus free GSH in a CCl4 injury model, lowering MDA/NO and inflammatory markers and improving histology, consistent with enhanced oral bioavailability. Review‑level evidence summarizes liposomal GSH usage around 50 mg/kg/day in animals, and a rheumatoid arthritis rat model reported biomarker improvements with liposomal GSH at 5 mg/kg/day over 30 days. These illustrate formulation‑dependent dose levels and outcomes, though not classic dose‑response curves (see table).

Embedded summary table of doses, routes, regimens, and outcomes:

Interpretation across studies:

• Effective IV rescue dose in acute hepatic injury models is 200 mg/kg given within hours of insult, with clear biochemical benefit.
• For oral GSH, doses from ~123 to ~1,229 mg/kg produce tissue GSH increases in a dose‑dependent but saturable fashion at ≈90 min, with functional protection observed at higher single doses (≈1,000 mg/kg) in toxin models.
• High‑dose IP regimens (≈500 mg/kg) have been used experimentally for nephro‑/neuroprotection with cisplatin, but more granular dose‑response within those models is limited in the excerpts; nonetheless, these data support feasibility and protective effects at that dose range (see table).

Limitations: Classical graded dose–response curves for clinical outcomes are best established for oral tissue GSH levels (0.4–4 mmol/kg) rather than for hard outcomes like survival. Some entries (e.g., cisplatin models, nanoformulations) derive from snippets lacking full numerical effect sizes in our excerpts, though they contribute concrete dose and regimen context.

Administration Routes#

We compared oral, subcutaneous (SC), intramuscular (IM), and topical administration of reduced glutathione (GSH), focusing on bioavailability and route-specific pharmacokinetics (PK). A structured summary is provided in the embedded table, followed by a concise narrative.

Oral administration

• Bioavailability and systemic exposure: Free oral GSH generally shows low and highly variable systemic bioavailability due to degradation by intestinal γ‑glutamyltranspeptidase, with inconsistent increases in plasma/whole‑blood GSH across studies. Formulations designed to improve stability and uptake (e.g., S‑acetyl‑GSH, liposomal or orobuccal nano GSH) can measurably raise circulating or erythrocyte GSH, albeit with substantial interindividual variability (fanelli2018clinicalnutrition& pages 1-2, md2022dietaryγglutamylcysteineits pages 5-7).
• Quantitative PK: A single‑dose human comparison of S‑acetyl‑GSH (3.494 g) versus a reference reduced GSH product (3.5 g) reported plasma GSH Cmax ≈0.74±0.41 µM vs 0.47±0.24 µM, median Tmax ≈1.5 h for both, and AUC0–t ≈3.90±4.07 vs 2.31±3.38 µM·h, respectively. Erythrocyte GSH responses were variable. The authors also note a very short plasma half‑life for free GSH on the order of minutes, consistent with rapid extracellular metabolism and redox turnover (fanelli2018clinicalnutrition& pages 4-6). Reviews and clinical commentaries align that oral free GSH has limited and inconsistent systemic bioavailability (fanelli2018clinicalnutrition& pages 1-2, md2022dietaryγglutamylcysteineits pages 5-7).

Parenteral administration (SC and IM)

• Evidence availability: We did not identify human studies reporting quantified plasma time–concentration PK (Cmax, Tmax, AUC, half‑life) after SC or IM GSH injections. Therefore, route‑specific numerical bioavailability and absorption‑phase parameters for reduced GSH via SC/IM remain unquantified in the present evidence set (md2022dietaryγglutamylcysteineits pages 5-7).
• Inference and disposition context: By parenteral principles, SC and IM routes bypass gastrointestinal hydrolysis and are expected to achieve substantially higher systemic availability than oral dosing for small peptides. Once in the circulation, exogenous GSH is rapidly metabolized/oxidized. Human IV studies document rapid degradation of GSH with short circulating half‑life (on the order of minutes to ~10 min), and a shift toward metabolites such as cysteine; these features inform expected systemic disposition irrespective of parenteral entry route, although absorption kinetics and potential depot effects specific to SC/IM for GSH have not been formally quantified.

Topical administration

• Systemic absorption and PK: Conventional cutaneous delivery of peptides has low systemic bioavailability, and formal plasma PK curves (Cmax, Tmax, AUC) for topical GSH creams/lotions are generally not reported. However, a pilot human study using a topical glutathione–cyclodextrin nanoparticle formulation showed increased intracellular GSH in PBMCs and RBCs and immunologic changes (elevated plasma cytokines) at 72 h after application, indicating systemic biological effects without a reported plasma GSH PK profile. Thus, systemic exposure appears formulation‑dependent, with nanoparticle or cyclodextrin approaches showing promise, but quantitative PK remains uncharacterized for cutaneous products.

Mechanistic notes across routes

• Oral GSH faces enzymatic hydrolysis in the gut; strategies to enhance bioavailability include prodrugs (e.g., S‑acetyl‑GSH), liposomal/nanoencapsulation, and precursors (e.g., γ‑glutamylcysteine) that can be converted intracellularly. Despite these strategies, intersubject variability remains high and plasma half‑life of circulating free GSH is short (fanelli2018clinicalnutrition& pages 4-6, md2022dietaryγglutamylcysteineits pages 5-7).
• Parenteral GSH avoids first‑pass hydrolysis but undergoes rapid extracellular metabolism/oxidation; human IV studies show rapid appearance/disappearance of GSH and changes in sulfur‑containing metabolites, consistent with a short circulating half‑life and redistribution to metabolite pools.

Conclusions

• Oral free GSH: low and variable bioavailability; S‑acetyl and specialized formulations can raise blood GSH modestly, with reported plasma Cmax ≲1 µM and Tmax ≈1.5 h in single‑dose testing; plasma half‑life is very short (minutes) (fanelli2018clinicalnutrition& pages 4-6, fanelli2018clinicalnutrition& pages 1-2, md2022dietaryγglutamylcysteineits pages 5-7).
• SC/IM GSH: direct human PK for reduced GSH is not yet quantified. Systemic bioavailability is expected to exceed that of oral dosing because parenteral routes bypass GI degradation, but absorption kinetics (Cmax/Tmax/AUC) and depot behavior specific to GSH remain an evidence gap; disposition will mirror IV context of rapid oxidation/metabolism.
• Topical GSH: standard creams likely have low systemic bioavailability; nanoparticle/cyclodextrin formulations can produce systemic biomarker changes within ~72 h, but plasma PK parameters have not been defined in humans.

Overall, among the requested routes, only oral formulations (notably S‑acetyl‑GSH) have human PK numbers reported for circulating GSH, whereas SC/IM and topical routes have either no human PK quantification (SC/IM) or only biomarker‑based systemic signals without classical PK (topical). Further standardized PK studies are needed to establish bioavailability and absorption kinetics for SC/IM and to quantify systemic exposure from topical formulations.

Oral Administration#

• Oral dosing in rats and mice (standard GSH): Oral GSH at 1 g/kg (≈3.26 mmol/kg) increased hepatic GSH in fasted rats and accelerated recovery after diethyl maleate (DEM) depletion; in mice challenged with high‑dose paracetamol (≈900 mg/kg), oral GSH partially prevented the hepatic GSH fall and improved metabolic and enzyme markers versus toxin alone. Mechanistically, portal cysteine rose after dosing, consistent with intestinal breakdown and hepatic resynthesis. Regimens were single doses with time‑course sampling up to 24 h.

Human-Equivalent Dosing#

Question How are animal study doses of glutathione (GSH) scaled to human-equivalent doses (HED), and what allometric scaling methods have been used in the literature?

In practice, investigators translate animal antioxidant doses—including GSH or interventions acting via the glutathione system—using three complementary approaches: (1) body-surface-area (BSA) normalization with Km factors to compute an HED in mg/kg; (2) power-law allometric scaling of pharmacokinetics (especially clearance) and back-calculation of a human dose that recreates the preclinical systemic exposure (AUC); and (3) mechanistic scaling using PBPK/PK–PD to match target-tissue exposure or metabolite formation (including GSH-conjugation flux), rather than administered dose. Because oral GSH has poor systemic bioavailability and route/formulation strongly alter exposure, simple BSA translation should be adjusted by route-specific pharmacokinetics or replaced by exposure-matching models when possible (e.g., for intravenous vs oral, or nanoformulations). Concrete formulas, species factors, and examples are below.

Methods in common use and formulas

• BSA (Km) method (FDA-style). Convert an animal mg/kg dose to a human mg/kg HED with: HED (mg/kg) = animal dose (mg/kg) × (Km_animal / Km_human). Representative Km values: mouse ≈ 3.0; rat ≈ 5.9–6.2; monkey ≈ 12; dog ≈ 20; adult human ≈ 37. Example: a 20 mg/kg mouse dose corresponds to ≈1.62 mg/kg in humans [20 × (3/37)], or ≈113 mg for a 70-kg adult (commonly used by investigators and reproduced in worked examples). Equivalent weight-based expression: HED = animal mg/kg × (BW_animal/BW_human)^(1/3). Using a 0.3-kg rat and a 70-kg human yields an interspecies scaling factor (ISF) of 6.16; for a 0.03-kg mouse the ISF is 13.3. FDA-style tables using the 0.67 exponent give convenient factors: divide a mouse mg/kg dose by ~12.3 (multiply by 0.081); divide a rat mg/kg dose by ~6.2 (multiply by 0.162).
• PK allometric scaling and exposure matching. Scale clearance with Y = a·W^b (typical b ≈ 0.6–0.8), predict human clearance from multi-species data, then compute a human dose as AUC_target × CL_human. The Rule of Exponents guides whether to correct simple allometry with maximum lifespan potential or brain weight, and unbound fraction (fu) corrections can improve predictions; this method is routinely used to derive minimal-risk starting doses when PK is linear and the parent drives effect. This approach guards against route-dependent bioavailability differences that can confound direct mg/kg scaling (hunter2010interspeciesallometricscaling. pages 4-7, hunter2010interspeciesallometricscaling. pages 12-15).
• Mechanistic PBPK/target-tissue dose scaling. When toxicity or efficacy tracks a glutathione-dependent metabolite, scaling should target the same tissue exposure metric across species. In methylene chloride, cancer risk correlated with the amount metabolized via GSH conjugation per tissue volume per day; PBPK models were used to identify human exposures that reproduce the mouse GSH-conjugation tissue dose, decomposing the interspecies scaling factor into PK (ISF-1) and pharmacodynamic (ISF-2) components.

How this has been applied around the glutathione system and for GSH

• Papers in the oxidative stress/GSH enzyme domain explicitly use BSA/Km translation to present HEDs from mouse studies. For example, a study administering 20 mg/kg/day sesame lignans to mice (which upregulated GSTA1/A4 and GSTM4) reported an HED of 1.63 mg/kg (~98–100 mg/day for a 60-kg person) using a surface-area formula. Such practice is typical when reporting antioxidant nutraceutical doses.
• Oral glutathione itself has poor bioavailability due to intestinal γ‑glutamyltransferase; formulation and route dramatically change exposure. Nano-formulations (niosomes) increased hepatic GSH exposure and efficacy in rats versus conventional oral GSH, underscoring that an HED based only on BSA may misestimate human exposure unless route/formulation PK is considered. Broader antioxidant delivery reviews similarly show orders-of-magnitude differences in exposure and efficacy across routes and formulations (e.g., NAC and α‑tocopherol), reinforcing the need for exposure-matched scaling rather than pure mg/kg conversion when changing route or formulation.

Species factors and worked examples

• Mouse to human (adult): Km_mouse/Km_human ≈ 3/37 ≈ 0.081. Thus 50 mg/kg in mice ≈ 4.05 mg/kg in humans (~284 mg for 70 kg). The alternative BW^(1/3) form gives a similar result when using nominal 0.02–0.03 kg mouse and 60–70 kg human.
• Rat to human (adult): Km_rat/Km_human ≈ 5.9–6.2/37 ≈ 0.16–0.17. Thus 100 mg/kg in rats ≈ 16–17 mg/kg in humans (~1.1 g for 70 kg). The EPA-style BW^(1/3) factor for a 0.3‑kg rat to 70‑kg human is ~1/6.16.
• Dog to human (adult): Km_dog/Km_human ≈ 20/37 ≈ 0.54. Thus 10 mg/kg in dogs ≈ 5.4 mg/kg in humans (~380 mg for 70 kg).
• Safety factors and starting doses: BSA-based HEDs are commonly divided by a default safety factor (often 10) when selecting a first-in-human dose; alternative pharmacokinetically guided approaches compute a starting dose from animal AUC and predicted human clearance and then apply a safety factor.

Caveats specific to glutathione/GSH

• Bioavailability and route: Oral reduced GSH is limited by enzymatic degradation; intravenous, inhaled, or nano-encapsulated preparations can yield very different systemic and tissue exposures. Hence, translate by exposure (AUC, Cmax, or target-tissue GSH increment) rather than by mg/kg alone when changing route or formulation.
• Mechanistic drivers: For xenobiotics whose toxicity or efficacy depends on GSH conjugation or GST activity, match the mechanistic tissue dose (e.g., metabolite formation rate per tissue volume) across species using PBPK, not just mg/kg scaling.
• Allometry limits: Scaling is most reliable when PK is linear and elimination pathways are conserved; many compounds are not reliably scalable across diverse species. Size-independent species differences in PK/PD and protein binding can bias allometric exponents; fu-corrections and multi-species regression mitigate this.

Practical guidance for translating animal GSH-related dosing

• If only an animal mg/kg dose is available and route/formulation are to be maintained in humans, compute an HED with the Km method and then adjust for known bioavailability differences or apply a safety factor for first-in-human use.
• If PK data exist (AUC, CL), predict human clearance via allometry and select a human dose to match the efficacious animal AUC; apply safety factors as appropriate.
• If mechanism depends on GSH conjugation/tissue redox endpoints, use PBPK to match tissue exposure or metabolite flux. For oral reduced GSH specifically, consider the large route/formulation effect on exposure before equating mg/kg doses.

Key sources

• BSA/Km method with explicit Km values, formula, and example calculation; FDA-style endorsement and tables.
• PK allometry, Rule of Exponents, fu-corrections, and AUC×CL dose derivation.
• PBPK and interspecies scaling decomposed into PK and PD terms; example anchored to GSH conjugation (methylene chloride).
• GSH domain caveats on bioavailability/route and a worked HED example in a GST-upregulation study.

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Related Reading#

• Glutathione overview and research guide
• Glutathione side effects profile
• Glutathione research evidence